The Organ Transplant Recipient HPV and Skin Cancer Study
- Conditions
- Skin DysplasiaHPV InfectionCervical CancerSkin CancerCervical Intraepithelial NeoplasiaHPV-Related MalignancySolid Organ Transplant Recipient
- Interventions
- Other: No intervention
- Registration Number
- NCT05284877
- Lead Sponsor
- Merete Haedersdal
- Brief Summary
Solid organ transplant recipients (OTRs) receive lifelong immunosuppressive therapy, which puts them at increased risk of cutaneous and mucosal cancers. In particular, OTRs have increased risk of skin cancer and cancers caused by human papillomavirus (HPV), including cervical cancer and oropharyngeal cancer. There is currently limited knowledge on risk factors for HPV infection and skin cancer in OTRs, and limited knowledge on the natural history of HPV infection and cervical neoplasia in OTRs compared with immunocompetent controls. With a continuously increasing number of OTRs, there is a growing need to improve our understanding of the long-term reactions to immunosuppression.
The overall aim of this study is to investigate long term effects of immunosuppression on cutaneous and mucosal epithelium in Danish OTRs, including the risk of skin dysplasia and skin cancer, cervical and oral HPV infection and HPV-related dysplasia and cancer in OTRs.
This study will be designed as a prospective observational cohort study based on clinical data and data from nationwide Danish registries. A total of 600 female OTRs, 300 male OTRs and 600 female controls will be included from Danish dermatology departments.
The study aims to provide knowledge relevant for improving prevention of skin- and HPV-related cancers in OTRs, including personalized screening recommendations according to individual patient risk.
- Detailed Description
AIMS
The specific research objectives of this study are:
1. To investigate the overall and type-specific prevalence, incidence and persistence of cervical HPV infection in OTRs compared to immunocompetent controls.
2. To investigate the overall and type-specific prevalence of oral HPV infection in female OTRs compared to immunocompetent controls.
3. To determine the role of lifestyle and clinical factors for the occurrence of cervical and oral HPV infection in female OTRs.
4. To investigate the prevalence and incidence of HPV-related dysplasia and cancer in female OTRs compared with immunocompetent controls.
5. To determine the role of lifestyle, clinical and organ transplantation-related factors for the prevalence and incidence of skin dysplasia in OTRs.
6. To investigate associations between skin dysplasia and prevalence of cervical HPV infection and VZV infection in OTRs.
METHODS
The study will be designed as a clinical prospective cohort study. A total of 600 female OTRs, 300 male OTRs and 600 female immunocompetent controls will be included from the Departments of Dermatology at Bispebjerg, Gentofte and Roskilde Hospitals, Denmark.
The following data will be collected from OTRs:
* At baseline: Questionnaire, dermatologic skin assessment, assessment of skin photodamage (only OTRs recruited from Bispebjerg Hospital), medical record information, cervico-vaginal HPV self-sample test (women only), oral sample for HPV test (women only), blood sample for future research, blood sample for vitamin D test (only OTRs recruited from Bispebjerg Hospital).
* After 6 months: New blood sample for vitamin D test (only OTRs recruited from Bispebjerg Hospital).
* After 12 months: New cervico-vaginal HPV self-sample test (women only).
The following data will be collected from female immunocompetent controls:
* At baseline: Questionnaire, cervico-vaginal HPV self-sample test, oral sample for HPV test.
* After 12 months: New cervico-vaginal HPV self-sample test.
A REDCap database will be established for study data. The RedCap database is encrypted and accessed electronically with personal user-ID and password.
The study population will be linked with nationwide Danish registries and clinical databases. From these registers information on cases of precancerous lesions and cancer; other HPV-related conditions; participation in HPV vaccination and cervical cancer screening; co-morbidities, pregnancies, births and medicine use; socio-demographic characteristics; and emigration and death of women in the study population will be obtained. Registry linkage will be performed for up to 15 years after end of study.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 1500
Not provided
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Female organ transplant recipients No intervention 600 women with a solid organ transplant (heart, lung, liver, kidney or pancreas) Female immunocompetent controls No intervention 600 immunocompetent women without organ transplant or other immunosuppressive conditions/treatments Male organ transplant recipients No intervention 600 men with a solid organ transplant (heart, lung, liver, kidney or pancreas)
- Primary Outcome Measures
Name Time Method Difference in prevalence, incidence and persistence of cervical HPV infection in female OTRs compared to immunocompetent controls. Evaluated at baseline and month 12 Number of women with cervical HPV infection measured by PCR test.
- Secondary Outcome Measures
Name Time Method Difference in prevalence and incidence of HPV-related dysplasia and cancer in female OTRs compared to immunocompetent controls. Evaluated at baseline and during up to 15 years after baseline. Number of women with HPV-related dysplasia and HPV-related cancer from registries using registry linkage.
Correlations between lifestyle factors, clinical factors and prevalence of skin dysplasia and cancer in OTRs. Evaluated at baseline Lifestyle factors determined by a questionnaire. Clinical factors from medical records. Skin dysplasia and skin cancer assessed by clinical evaluation and by non-invasive imaging.
Correlation between prevalence of cervical HPV infection and prevalence of skin dysplasia and cancer in OTRs. Evaluated at baseline Number of women with cervical HPV infection measured by PCR test. Skin dysplasia and skin cancer assessed by clinical evaluation and non-invasive imaging.
Difference in prevalence of oral HPV infection in female OTRs compared to immunocompetent controls. Evaluated at baseline Number of women with oral HPV infection measured by PCR test.
Correlations between lifestyle factors, clinical factors and occurrence of cervical HPV infection in female OTRs. Evaluated at baseline Lifestyle factors determined by questionnaire. Clinical factors from medical records. Number of women with cervical HPV infection measured by PCR test.
Correlation between Vitamin D and prevalence of skin dysplasia and cancer in OTRs. Evaluated at baseline Vitamin D from blood sample analysis. Skin dysplasia and skin cancer assessed by clinical evaluation and non-invasive imaging.
Correlations between lifestyle factors, clinical factors and occurrence of oral HPV infection in female OTRs. Evaluated at baseline Lifestyle factors determined by questionnaire. Clinical factors from medical records. Number of women with oral HPV infection measured by PCR test.
Correlations between skin pigmentation, facial solar lentigines and prevalence of skin dysplasia and cancer in OTRs. Evaluated at baseline Skin pigmentation measured with skin reflectance. Facial solar lentigines measured by photographs. Skin dysplasia and skin cancer assessed by clinical evaluation and non-invasive imaging.
Correlations between history of herpes zoster, prevalence of cervical HPV infection and prevalence of skin dysplasia and cancer in OTRs. Evaluated at baseline Number of women with history of herpes zoster determined by questionnaire. Number of women with cervical HPV infection measured by PCR test. Skin dysplasia and skin cancer assessed by clinical evaluation and non-invasive imaging.
Difference in prevalence and incidence of skin cancer in female OTRs compared to immunocompetent controls. Evaluated at baseline and during up to 15 years after baseline. Number of women with skin cancer from registries using registry linkage
Trial Locations
- Locations (3)
Department of Dermatology, Bispebjerg Hospital
🇩🇰Copenhagen NV, Region Hovedstaden, Denmark
Department of Dermatology and Allergy, Herlev og Gentofte Hospital
🇩🇰Hellerup, Region Hovedstaden, Denmark
Department of Dermatology, Zealand University Hospital
🇩🇰Roskilde, Region Sjælland, Denmark